Literature DB >> 17071541

Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.

Thomas C Baghai1, Hans-Peter Volz, Hans-Jürgen Möller.   

Abstract

During the past 10 years our knowledge about the pharmacotherapy of depression has been consolidated, and a variety of very interesting new compounds launched onto the market. The pipeline of the pharmaceutical industry is still filled with an assortment of new developments and very promising new approaches towards the pharmacotherapy of depressive disorders. Future pharmacological treatments of depression will not only enhance serotonergic and noradrenergic neurotransmission: other systems, such as the melatonergic receptor system and the hypothalamus-pituitary-adrenal axis, are also the targets of newly developed and upcoming substances with putative antidepressant effects. The main advantages of the currently available newer pharmacotherapeutic options are the broadening of the spectrum of possible antidepressant treatments, which is of particular importance for the growing number of patients suffering from difficult-to-treat depression, and a far better tolerability profile in comparison to older compounds such as tricyclic antidepressants. Unresolved issues are the unacceptably high rate of non-responsiveness during antidepressant treatment, a latency of sometimes several weeks until clinical improvement and remission can be achieved, and a variety of possible side effects also present during treatment with modern compounds. This review mainly presents the development of antidepressant pharmacotherapies during the past 10 years, together with pharmacokinetic and pharmacodynamic information and a comparison of different pharmacological treatment principles evaluated in randomized controlled clinical trials. In addition, new pharmacological strategies that are not yet available on the market and strategies currently under development are reviewed in detail. The study of new treatment options is of major importance to provide better strategies for the clinical management of depression in the future, and is thus also of great socio-economic importance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17071541     DOI: 10.1080/15622970601003973

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  9 in total

1.  Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008.

Authors:  Hans Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11-19       Impact factor: 5.270

Review 2.  Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement.

Authors:  Hans-Jürgen Möller; David S Baldwin; Guy Goodwin; Siegfried Kasper; Ahmed Okasha; Dan J Stein; Rajiv Tandon; Marcio Versiani
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-08       Impact factor: 5.270

3.  Outcome and length of stay in psychiatric hospitalization, the experience of the University Clinic of Turin.

Authors:  Paola Rocca; C Mingrone; T Mongini; C Montemagni; L Pulvirenti; G Rocca; F Bogetto
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-07-08       Impact factor: 4.328

Review 4.  Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-12-01       Impact factor: 5.270

Review 5.  Clinical trial design in non-invasive brain stimulation psychiatric research.

Authors:  André Russowsky Brunoni; Felipe Fregni
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

6.  Clinical outcome and length of stay in an Italian Psychiatric Emergency Service.

Authors:  T Frieri; C Montemagni; G Rocca; P Rocca; V Villari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-30       Impact factor: 4.328

7.  Getting the balance right: Established and emerging therapies for major depressive disorders.

Authors:  Bojana Perović; Marija Jovanović; Branislava Miljković; Sandra Vezmar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 8.  Agomelatine: innovative pharmacological approach in depression.

Authors:  Maurizio Popoli
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

9.  Organic Cation Transporters in Psychiatric Disorders.

Authors:  Lynette C Daws
Journal:  Handb Exp Pharmacol       Date:  2021
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.